2024-516333-12-00招募中1 期
A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast cancer.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
Thomas K. Jorgensen
Scientific
Expres2ion Biotechnologies ApS
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A First in Human trial to study safety and tolerability of single rising intravitreal doses (oPen label, non-randomized, uncontrolled) and in Addition the early biological Response of mulTiple intravitreal doses (double-masked, RandomIzed, shamcontrolleD) of BI 765128 in panretinal photocoaGulation (PRP) treated diabetic rEtinopathy (DR) patients with diabetic macular ischemia (DMI) - the PARTRIDGE StudyDiabetic Macular IschemiaDMI10047061NL-OMON53613Boehringer Ingelheim1
已完成
1 期
A first-in-human study to evaluate the safety, tolerability and performance of uncoated and placebo-coated NanopatchesVaccination Delivery DeviceOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000583549Vaxxas Pty Ltd18
进行中（未招募）
不适用
CBPR277X2101Part 2: Atopic Dermatitis (AD)Part 3: Netherton Syndrome (NS)MedDRA version: 14.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858MedDRA version: 14.1Level: PTClassification code 10062909Term: Netherton's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000917-38-DEovartis Pharma Services AG85
进行中（未招募）
不适用
CBPR277X2101EUCTR2011-000917-38-NLovartis Pharma Services AG85
已完成
2 期
A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome (CBPR277X2101)Netherton syndrome10040790NL-OMON40034ovartis Pharma BV5